Limits...
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus

Clinical outcomes of cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, and all-cause mortality by age category and treatment group. Rates are expressed as a rate per 100 patient-years of treatment (error bars are 95% confidence intervals).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595742&req=5

EHV330F1: Clinical outcomes of cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, and all-cause mortality by age category and treatment group. Rates are expressed as a rate per 100 patient-years of treatment (error bars are 95% confidence intervals).

Mentions: The unadjusted incidence of the primary composite outcome of CV death or hospitalization for heart failure according to age is shown in Table 2 and Figure 1A. The incidence of this endpoint in the enalapril (control) group did not vary greatly across the age categories up to 65–74 years but was somewhat higher in those aged 75 years or above.Table 2


Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

Clinical outcomes of cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, and all-cause mortality by age category and treatment group. Rates are expressed as a rate per 100 patient-years of treatment (error bars are 95% confidence intervals).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595742&req=5

EHV330F1: Clinical outcomes of cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, and all-cause mortality by age category and treatment group. Rates are expressed as a rate per 100 patient-years of treatment (error bars are 95% confidence intervals).
Mentions: The unadjusted incidence of the primary composite outcome of CV death or hospitalization for heart failure according to age is shown in Table 2 and Figure 1A. The incidence of this endpoint in the enalapril (control) group did not vary greatly across the age categories up to 65–74 years but was somewhat higher in those aged 75 years or above.Table 2

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus